Aug. 17 at 3:44 PM
$FRNM Jefferies initiated coverage on Freenome (NASDAQ: FRNM) with a Buy rating and a
$17.00 price target, pointing to an upcoming commercial boost from expected health insurer reimbursements for its blood-based early cancer detection tests.
Jefferies initiated coverage on Freenome (NASDAQ: FRNM) with a Buy rating and a
$17.00 price target, pointing to an upcoming commercial boost from expected health insurer reimbursements for its blood-based early cancer detection tests